Zhu Jiayu, Wei Biyu, Wu Lili, Li He, Zhang Yi, Lu Jinfeng, Su Shaofei, Xi Chunhua, Liu Wei, Wang Guyan
Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
Department of Anesthesiology, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Ther Clin Risk Manag. 2025 May 15;21:691-703. doi: 10.2147/TCRM.S515093. eCollection 2025.
TPVB can provide effective postoperative analgesia in lung cancer patients undergoing video-assisted thoracoscopic surgery (VATS), which may enhance respiratory mechanics and postoperative expectoration, as well as relieve inflammation and stress. These mechanisms may reduce the incidence of postoperative pulmonary complications (PPCs). This study explored whether TPVB reduces the risk of PPCs in patients undergoing VATS for lung cancer.
In this dual-center trial, patients who underwent VATS for lung cancer were randomly divided into the PV group (n = 151, general anesthesia [GA] and TPVB) and the C group (n = 151, GA only). The primary outcome was the incidence of a composite of PPCs within seven days postoperatively.
The incidence of PPCs within seven days postoperatively was lower in the PV group (37.7%, 57/151) compared to the C group (49.0%, 74/151), with a risk ratio of 1.59 (95% CI: 1.00 to 2.50, =0.048). And within 8-30 days postoperatively, compared with that in the C group (33.1%, 50/151), the incidence of PPCs was lower in patients in the PV group (22.5%, 34/151), with a risk ratio of 1.70 (95% CI, 1.02 to 2.84, =0.040). There was a significant difference in the incidence of pneumonia between the PV group (11/151, 7.3%) and the C group (35/151, 23.3%; < 0.001), and the incidence of pneumothorax between the PV group (27/151, 17.9%) and the C group (45/151, 29.8%; = 0.015).
Compared to GA alone, TPVB combined with GA reduces the incidence of PPCs within seven days postoperatively in patients undergoing VATS for lung cancer, and this beneficial effect can last up to 30 days after surgery. A possible mechanism is that TPVB reduces acute postoperative pain in patients.
胸椎旁神经阻滞(TPVB)可为接受电视辅助胸腔镜手术(VATS)的肺癌患者提供有效的术后镇痛,这可能会改善呼吸力学和术后咳痰情况,减轻炎症和应激反应。这些机制可能会降低术后肺部并发症(PPCs)的发生率。本研究探讨了TPVB是否能降低接受VATS治疗肺癌患者发生PPCs的风险。
在这项双中心试验中,接受VATS治疗肺癌的患者被随机分为PV组(n = 151,全身麻醉[GA]联合TPVB)和C组(n = 151,仅GA)。主要结局是术后7天内PPCs综合发生率。
术后7天内,PV组PPCs发生率(37.7%,57/151)低于C组(49.0%,74/151),风险比为1.59(95%CI:1.00至2.50,P = 0.048)。术后8至30天内,与C组(33.1%,50/151)相比,PV组患者PPCs发生率较低(22.5%,34/151),风险比为1.70(95%CI,1.02至2.84,P = 0.040)。PV组(11/151,7.3%)与C组(35/151,23.3%;P < 0.001)之间肺炎发生率存在显著差异,PV组(27/151,17.9%)与C组(45/151,29.8%;P = 0.015)之间气胸发生率也存在显著差异。
与单纯GA相比,TPVB联合GA可降低接受VATS治疗肺癌患者术后7天内PPCs的发生率,且这种有益作用可持续至术后30天。一种可能的机制是TPVB减轻了患者术后的急性疼痛。